Cambrian Biopharma co-led a $28.5m round for cancer immunotherapy developer Sensei Biotherapeutics with venture capital firm H&S Ventures.
Sensei Biotherapeutics, a US-based biopharmaceutical company targeting cancer and infectious diseases, has raised $28.5m in a series A round co-led by Cambrian Biopharma, a research group targeting ageing.
Venture capital firm H&S Ventures co-led the round, which included Steve Jurvetson’s new venture capital firm, Future Ventures, Christian Angermayer’s Apeiron Investment Group and Presight Ventures, the US branch of Apeiron Investment Group.
Formerly known as Panacea Pharmaceuticals, Sensei will use the money to develop a technology platform to discover novel classes…
